Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
- G. von Minckwitz, M. Untch, S. Loibl
- MedicineJournal of Clinical Oncology
- 20 May 2012
PURPOSE
The exact definition of pathologic complete response (pCR) and its prognostic impact on survival in intrinsic breast cancer subtypes is uncertain.
METHODS
Tumor response at surgery and its…
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
- I. Smith, M. Procter, M. Piccart-Gebhart
- MedicineThe Lancet
- 6 January 2007
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
- R. Jakesz, W. Jonat, M. Kaufmann
- MedicineThe Lancet
- 6 August 2005
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
- O. Abe, R. Abe, L. Martino
- MedicineThe Lancet
- 14 May 2005
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors
- M. Filipits, M. Rudas, M. Gnant
- MedicineClinical Cancer Research
- 1 August 2011
A gene expression signature predicting the likelihood of distant recurrence in patients with estrogen receptor–positive, HER2-negative breast cancer treated with adjuvant endocrine therapy is developed and validated.
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.
- M. Kaufmann, G. Hortobagyi, G. von Minckwitz
- MedicineJournal of Clinical Oncology
- 20 April 2006
A second international panel of representatives of a number of breast cancer clinical research groups was convened in September 2004 to update recommendations regarding neoadjuvant treatment for operable disease and data published to date were reviewed critically and indications were newly defined.
Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
- M. Kaufmann, W. Jonat, G. von Minckwitz
- MedicineJournal of Clinical Oncology
- 1 July 2007
Postmenopausal women who have taken tamoxifen for 2 years as adjuvant therapy are less likely to experience a recurrence of breast cancer and have improved overall survival if they switch to anastrozole compared with continuing to receive tamoxIFen.
Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer
- M. Kaufmann, G. Minckwitz, L. Pusztai
- MedicineAnnals of Surgical Oncology
- 1 May 2012
The use of neoadjuvant systemic therapy for the treatment of primary breast cancer has constantly increased, especially in trials of new therapeutic regimens and therapies that use NST are aimed to precede and anticipate the results from larger adjuvant trials.
Reduction in new metastases in breast cancer with adjuvant clodronate treatment.
- I. Diel, E. Solomayer, G. Bastert
- MedicineNew England Journal of Medicine
- 6 August 1998
Clodronate can reduce the incidence and number of new bony and visceral metastases in women with breast cancer who are at high risk for distant metastases.
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
- A. Rody, U. Holtrich, M. Kaufmann
- Biology, MedicineBreast Cancer Research
- 9 March 2009
Precise definitions of the specific subtypes of immune cells in the tumor can be accomplished from microarray data, and all known prognostic gene signatures uniformly assign poor prognosis to all ER-negative tumors.
...
...